ALLO Earnings Date: Nov 5, 2026 (Estimated) — Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ALLO's next earnings date?
Allogene Therapeutics, Inc. (ALLO) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.15 on revenue of $2,500.
How did ALLO do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Allogene Therapeutics, Inc. posted EPS of -$0.13 versus the -$0.17 estimate, a beat of 13.3%. Revenue was $4.6M against a $2,500 estimate. The stock's 1-day post-earnings move was -4.3%.
How much does ALLO stock move after earnings?
ALLO beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.1% (up or down) in the day after earnings.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.17 | -0.13 | +13.33% | $4.6M | ✅ Beat | -4.35% | +7.73% | -14.01% |
| 2026-05-13 | Q1 2026 | -0.18 | -0.18 | +0.00% | $0 | ➖ Inline | -8.15% | -18.45% | -18.45% |
| 2026-03-12 | Q4 2025 | -0.23 | -0.17 | +26.09% | $0 | ✅ Beat | -2.83% | -10.12% | +23.89% |
| 2025-11-06 | Q3 2025 | -0.23 | -0.19 | +17.39% | $0 | ✅ Beat | +12.38% | +14.29% | +38.10% |
| 2025-08-13 | Q2 2025 | -0.27 | -0.23 | +14.81% | $0 | ✅ Beat | +2.88% | +1.92% | +8.65% |
| 2025-03-13 | Q4 2024 | -0.34 | -0.28 | +17.65% | $0 | ✅ Beat | +2.65% | -13.76% | -23.28% |
| 2024-11-07 | Q3 2024 | -0.33 | -0.32 | +3.03% | $0 | ✅ Beat | -3.45% | -22.88% | -28.84% |
| 2024-08-07 | Q2 2024 | -0.35 | -0.35 | +0.00% | $0 | ➖ Inline | -4.45% | -8.91% | -2.43% |
Showing last 8 quarters.